Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 1999
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Primary revenue drivers are EPOGEN (Epoetin alfa) and NEUPOGEN (Filgrastim).
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 1999 |
6 Months Ended June 30, 1999 |
|---|---|---|
| Total Revenues | $820.5 | $1,566.0 |
| Net Income | $267.6 | $514.8 |
| Earnings Per Share (Diluted) | $0.50 | $0.96 |
| Operating Cash Flow | N/A | $565.1 |
| Cash & Marketable Securities | $1,368.3 | $1,368.3 |
| Total Debt (Long-term + Commercial Paper) | $322.8 | $322.8 |
| Cost of Sales Margin | 13.4% | 13.4% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 25% year-over-year for the quarter ($820.5M vs. $656.9M) and 24% for the six-month period ($1,566.0M vs. $1,262.3M).
- Product Sales: Product sales rose 21% for the quarter and 21% for the six months. EPOGEN sales grew 27% (quarter) and 28% (six months) due to higher dosing and patient population growth. NEUPOGEN sales grew 12% (quarter) and 11% (six months).
- Profitability: Net income increased 24% for the quarter ($267.6M vs. $216.3M) and 28% for the six months ($514.8M vs. $403.6M).
- Expenses: Research and development expenses increased 27% (quarter) and 25% (six months) due to staff costs and collaboration expenses. Selling, general, and administrative expenses increased 29% (quarter) and 23% (six months).
- Capital Allocation: The company repurchased 7 million shares for $470.7 million during the six-month period. Capital expenditures decreased to $147 million for the six months ended June 30, 1999, compared to $236 million in the prior year.
Guidance, Outlook, and Risks
Financial Outlook
- 1999 EPS Guidance: Management expects earnings per share to be at the high end of the range of $1.90 to $1.95, assuming the federal government extends the research and experimentation tax credit for the second half of 1999.
- Sales Growth: EPOGEN sales growth is expected to be in the mid-twenties for 1999. NEUPOGEN sales growth is expected to be high single- to low double-digits. Total product sales growth is anticipated in the high teens.
Management Commentary & Risks
- Reimbursement Risks: The Clinton administration has proposed a 10% cut in Medicare reimbursement for EPOGEN and a reduction in the reimbursement basis for NEUPOGEN (from 95% to 83% of Average Wholesale Price). The impact on Amgen is difficult to predict.
- Year 2000 Compliance: Amgen is not currently Year 2000 compliant. The company estimates total expenditures for the program will range from $45 million to $55 million, with approximately $27 million incurred as of June 30, 1999. There is a risk of operational disruption if compliance is not achieved or if third-party suppliers/payors fail to comply.
- Legal Contingencies: Ongoing arbitration with Johnson & Johnson regarding Epoetin alfa sales methodology and potential breach of license. Amgen has not recognized any benefit from potential fee recovery due to uncertainties. Other litigation includes patent disputes with Transkaryotic Therapies/Hoechst and Genentech.
Investor Verification Checklist
- Verify the status of the federal research and experimentation tax credit extension, as the 1999 EPS guidance depends on it.
- Monitor developments in the Johnson & Johnson arbitration regarding the audit methodology and potential damages for breach of license.
- Track the progress of the Year 2000 compliance program, specifically the readiness of critical suppliers and payors (e.g., HCFA).
- Watch for legislative or regulatory changes regarding Medicare reimbursement rates for EPOGEN and NEUPOGEN.
- Confirm the impact of cost containment pressures on NEUPOGEN sales growth in the U.S. and European markets.